Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic and Archemix Divide Aptamer Patent Estate

NEW YORK, Sept. 24 (GenomeWeb News) - SomaLogic has signed on to an IP alliance with Archemix, a biopharma based in Cambridge, Mass., for use of aptamers in diagnosis and therapeutics, the companies said Tuesday.


Under the agreement, SomaLogic, of Boulder, Colo., will have exclusive rights to diagnostics and ex vivo detection applications of aptamer technology, while Archemix has rights to therapeutics based on aptamers. For drug screening and target validation, the companies will cross-license the technologies.


The companies have also agreed to jointly "maintain , expand, and defend the aptamer patent estate," which includes over 150 patents and 100 patent applications, according to a press statement.


Aptamers are single-stranded nucleic acids will three-dimensional shapes that enable them to bind specifically to target molecules with high affinity.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.